Clinical Trial Update: Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612 [Phase 2]

View source ↗

Summary

A Phase 2 trial in adolescents and adults studied the long-term persistence (up to 3.5 years) of GSK Biologicals' meningococcal vaccine candidate 134612; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• GSK Biologicals Meningococcal Vaccine 134612

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 2 | Status: COMPLETED